{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:13:02Z","timestamp":1771661582384,"version":"3.50.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Numerous studies have focused on lymphoma among patients infected with human immunodeficiency virus (HIV). However, little is known about the treatment options and survival rate of lymphoma in the Chinese people living with HIV (PLHIV). Our study aimed to investigate the prognosis and compare outcome of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab(R-CHOP) as front line therapy for PLHIV with diffuse large B-cell lymphoma (DLBCL) receiving modern combined antiretroviral therapy (cART).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A retrospective analysis evaluating PLHIV with DLBCL was performed in Shanghai Public Health Clinical Center from July 2012 to September 2019. The demographic and clinical data were collected, and overall survival (OS) and progression-free survival (PFS) analyses of patients receiving R-CHOP or DA-EPOCH-R therapy were performed by Kaplan-Meier analysis. Additionally, a Cox multiple regression model was constructed to identify related factors for OS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 54 eligible patients were included in the final analysis with a median follow-up of 14 months (interquartile range [IQR]: 8\u201329 months). The proportion of high international prognostic index (IPI) patients was much larger in the DA-EPOCH-R group (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a29) than that in the R-CHOP group (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a25). The CD4 cell counts and HIV RNA levels were not significantly different between the two groups. The 2-year OS for all patients was 73%. However, OS was not significantly different between the two groups, with a 2-year OS rate of 78% for the DA-EPOCH-R group and 66% for the R-CHOP group. Only an IPI greater than 3 was associated with a decrease in OS, with a hazard ratio of 5.0. The occurrence of grade 3 and 4 adverse events of chemotherapy was not significantly different between the two groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Outcomes of R-CHOP therapy do not differ from those of DA-EPOCH-R therapy. No HIV-related factors were found to be associated with the OS of PLHIV in the modern cART era.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000001180","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T05:01:05Z","timestamp":1604638865000},"page":"2796-2802","source":"Crossref","is-referenced-by-count":7,"title":["Clinical outcomes of people living with human immunodeficiency virus (HIV) with diffuse large B-cell lymphoma (DLBCL) in Shanghai, China"],"prefix":"10.1097","volume":"133","author":[{"given":"Jian-Jun","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang-Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin-Zhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tang-Kai","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren-Fang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,12,5]]},"reference":[{"key":"R1-20231219","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJM200106073442306","article-title":"AIDS\u2013the first 20 years","volume":"344","author":"Sepkowitz","year":"2001","journal-title":"N Engl J Med"},{"key":"R2-20231219","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMp1502020","article-title":"Ending the HIV-AIDS pandemic--follow the science","volume":"373","author":"Fauci","year":"2015","journal-title":"N Engl J Med"},{"key":"R3-20231219","first-page":"e219766","article-title":"Spectrum of malignancies among the population of adults living with HIV infection in China: A nationwide follow-up study, 2008-2011","volume":"14","author":"Zhu","year":"2019","journal-title":"PLoS One"},{"key":"R4-20231219","doi-asserted-by":"crossref","first-page":"e2019004","DOI":"10.4084\/mjhid.2019.004","article-title":"Hiv and lymphoma: from epidemiology to Clinical Management","volume":"11","author":"Re","year":"2019","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R5-20231219","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1182\/blood-2018-01-791400","article-title":"Optimizing treatment of HIV-associated lymphoma","volume":"134","author":"Noy","year":"2019","journal-title":"Blood"},{"key":"R6-20231219","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1200\/JCO.2005.11.973","article-title":"AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy","volume":"23","author":"Lim","year":"2005","journal-title":"J Clin Oncol"},{"key":"R7-20231219","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/cam4.178","article-title":"Classification of AIDS-related lymphoma cases between 1987 and 2012 in Japan based on the WHO classification of lymphomas, fourth edition","volume":"3","author":"Ota","year":"2014","journal-title":"Cancer Med"},{"key":"R8-20231219","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"key":"R9-20231219","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/blood-2002-11-3589","article-title":"Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology","volume":"101","author":"Little","year":"2003","journal-title":"Blood"},{"key":"R10-20231219","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12879-017-2398-5","article-title":"Trends in baseline CD4 cell counts and risk factors for late antiretroviral therapy initiation among HIV-positive patients in Shanghai, a retrospective cross-sectional study","volume":"17","author":"Sun","year":"2017","journal-title":"BMC Infect Dis"},{"key":"R11-20231219","doi-asserted-by":"crossref","first-page":"e3802","DOI":"10.1097\/MD.0000000000003802","article-title":"Spectrum of opportunistic infections and risk factors for in-hospital mortality of admitted AIDS patients in Shanghai","volume":"95","author":"Luo","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R12-20231219","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13027-017-0120-2","article-title":"Clinical and prognostic analysis of 78 patients with human immuno-deficiency virus associated non-Hodgkin's lymphoma in Chinese population","volume":"12","author":"Shen","year":"2017","journal-title":"Infect Agent Cancer"},{"key":"R13-20231219","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdv036","article-title":"Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma","volume":"26","author":"Barta","year":"2015","journal-title":"Ann Oncol"},{"key":"R14-20231219","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/bjh.13221","article-title":"Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort","volume":"168","author":"Schommers","year":"2015","journal-title":"Br J Haematol"},{"key":"R15-20231219","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"R16-20231219","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13027-018-0200-y","article-title":"Prognostic factors in HIV-positive patients with non-Hodgkin lymphoma: a Peruvian experience","volume":"13","author":"Cuellar","year":"2018","journal-title":"Infect Agent Cancer"},{"key":"R17-20231219","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood-2009-11-253039","article-title":"The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma","volume":"115","author":"Dunleavy","year":"2010","journal-title":"Blood"},{"key":"R18-20231219","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1016\/j.clml.2019.05.019","article-title":"Patients with malignant lymphoma and HIV infection experiencing remission after first-line treatment have an excellent prognosis","volume":"19","author":"Kriegsmann","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R19-20231219","first-page":"862","article-title":"AIDS related lymphoma in Shanghai: a clinical analysis of 11 cases (in Chinese)","volume":"48","author":"Zhang","year":"2009","journal-title":"Chin J Intern Med"},{"key":"R20-20231219","first-page":"97","article-title":"Clinic pathological features and survival of patients with AIDS related non-Hodgkin's lymphoma (in Chinese)","volume":"38","author":"Sun","year":"2017","journal-title":"Chin J Hematol"},{"key":"R21-20231219","doi-asserted-by":"crossref","first-page":"18804","DOI":"10.7448\/IAS.17.1.18804","article-title":"Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIV-positive patients","volume":"17","author":"Boettiger","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"R22-20231219","doi-asserted-by":"crossref","first-page":"e96098","DOI":"10.1371\/journal.pone.0096098","article-title":"Baseline CD4 cell counts of newly diagnosed HIV cases in China: 2006\u20132012","volume":"9","author":"Tang","year":"2014","journal-title":"PLoS One"},{"key":"R23-20231219","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","article-title":"Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients","volume":"122","author":"Barta","year":"2013","journal-title":"Blood"},{"key":"R24-20231219","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2005.05.4684","article-title":"Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma","volume":"24","author":"Boue","year":"2006","journal-title":"J Clin Oncol"},{"key":"R25-20231219","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li","year":"2018","journal-title":"Pathology"},{"key":"R26-20231219","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1097\/QAD.0000000000001652","article-title":"Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era","volume":"31","author":"Besson","year":"2017","journal-title":"AIDS"},{"key":"R27-20231219","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/QAD.0000000000000133","article-title":"HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era","volume":"28","author":"Coutinho","year":"2014","journal-title":"AIDS"},{"key":"R28-20231219","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2014.59.5967","article-title":"Elevated cancer-specific mortality among HIV-infected patients in the United States","volume":"33","author":"Coghill","year":"2015","journal-title":"J Clin Oncol"},{"key":"R29-20231219","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/QAI.0000000000000184","article-title":"Survival after cancer in Italian persons with AIDS, 1986-2005: a population-based estimation","volume":"66","author":"Maso","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R30-20231219","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/hon.2536","article-title":"Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals","volume":"36","author":"Conconi","year":"2018","journal-title":"Hematol Oncol"},{"key":"R31-20231219","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/s41379-020-0506-3","article-title":"Identifying transcriptional profiles and evaluating prognostic biomarkers of HIV-associated diffuse large B-cell lymphoma from Malawi","volume":"33","author":"Fedoriw","year":"2020","journal-title":"Mod Pathol"},{"key":"R32-20231219","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/10428194.2017.1334121","article-title":"Novel tumor markers provide improved prediction of survival after diagnosis of human immunodeficiency virus (HIV)-related diffuse large B-cell lymphoma","volume":"59","author":"Chao","year":"2018","journal-title":"Leuk Lymphoma"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T16:09:39Z","timestamp":1703002179000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":32,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000001180","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,3]]}}}